Lupin inks pact with Alvion to market drugs in Southeast Asia
Drug maker Lupin on Tuesday said it has inked a licensing pact with Alvion Pharmaceuticals to commercialise medicines for cardio metabolic diseases in ...
Drug maker Lupin on Tuesday said it has inked a licensing pact with Alvion Pharmaceuticals to commercialise medicines for cardio metabolic diseases in ...
In its warning letter USFDA pointed out three major violations of current good manufacturing practices (cGMP) at Somerset site. These include firm's...
Lupin has launched its digital asthma educator platform.
Lupin has approached Gilead Sciences Inc for a voluntary license, or an authorisation given by a patent holder to a generics producer, to manufacture...
Lupin has approached Gilead Sciences Inc for a voluntary license, or an authorisation given by a patent holder to a generics producer, to manufacture...
The company has launched Posaconazole delayed-release tablets with the approval of the United States Food and Drug Administration (USFDA).
Drugmaker Lupin reported a net profit (profit after tax) of Rs 438.3 crore in the quarter ended December 31 led by growth of sales in the US, India...
Its alliance partner Concord Biotech received approval from FDA